Stephen Cunningham

Stephen is an experienced pharmaceutical executive with 30 years of expertise leading the development, approval, launch and lifecycle management of blockbuster drugs across multiple therapeutic areas. Prior to cofounding Engrail Therapeutics, Stephen gained broad portfolio experience at Zeneca and AstraZeneca. After 12 years at Zeneca/AstraZeneca, he spent 13 years at Novartis in the US as CSO and head of clinical development and medical affairs. Most recently, Stephen served as a key advisor to Chase Pharmaceuticals, Cipla Technologies and Pharmascience on the development of portfolios that led to high-value acquisitions. Stephen has extensive experience in the development of drugs in the neuroscience area and received his MD from Queen’s University Belfast.